Oncolytics Biotech Inc. (ONCY) Stock Analysis & Investment Frameworks
Oncolytics Biotech Inc. (ONCY) stock analysis on Invetso. Review Oncolytics Biotech Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Oncolytics Biotech Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Oncolytics Biotech Inc. Key Financial Metrics
- Market Cap: $50.20M
- Revenue: $N/A
- ROE: 1020.21%
- ROIC: -1480.50%
- Dividend Yield: N/A
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc. Investment Frameworks
Invetso analyzes Oncolytics Biotech Inc. (ONCY) across the following frameworks:
- Oncolytics Biotech Inc. 10Y Growth Potential
- Oncolytics Biotech Inc. Scenario Analysis
- Oncolytics Biotech Inc. Risks & Opportunities
- Oncolytics Biotech Inc. Economic Moat
- Oncolytics Biotech Inc. Business Model
- Oncolytics Biotech Inc. Management
- Oncolytics Biotech Inc. SWOT Analysis
- Oncolytics Biotech Inc. Porter's 5 Forces
- Oncolytics Biotech Inc. PESTLE Analysis
- Oncolytics Biotech Inc. ESG Analysis